No Picture
News

Genomic Testing Associated with Significantly Lower Health Care Costs in High-Risk Breast Cancer Patients, According to Researchers from Duke University

New study in JNCCN finds 21-gene assay was associated with savings of approximately $3,600 per patient in chemotherapy costs alone for people with clinically high-risk breast cancer.

PLYMOUTH MEETING, Pa., March 19, 2019 /PRNewswire/ — New research … […]

No Picture
News

Stereotaxis and Acutus Medical Combine Robotic Precision and High-Resolution Imaging to Treat Arrhythmias in First Integrated Procedures

– First patients successfully treated with robust integration of technologies- Integrated technologies now commercially available

ST. LOUIS and CARLSBAD, Calif., March 15, 2019 /PRNewswire/ — Stereotaxis (OTCQX: STXS) and Acutus Medical today announ… […]

No Picture
News

Sophiris Bio Reports Fourth Quarter 2018 and Year-end Financial Results and Recent Corporate Highlights

SAN DIEGO and VANCOUVER, British Columbia, March 13, 2019 /PRNewswire/ — Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company,” “We” or “Sophiris”), a biopharmaceutical company developing topsalysin (PRX302), a first-in-class, pore-forming protein, in la… […]

No Picture
News

Large Prospective Trial Validates Detection of AR-V7 Biomarker Using Epic Sciences’ Platform to Predict Treatment Outcomes for Patients with Advanced Prostate Cancer

PROPHECY validation trial published in Journal of Clinical Oncology

SAN DIEGO, March 13, 2019 /PRNewswire/ — Epic Sciences, Inc. (Epic) today announced the publication of results from a multicenter prospective trial validating the biomarker AR-V7 (a… […]

No Picture
News

Neurocrine Biosciences Reports Positive Interim Results from Phase II Study of NBI-74788 in Adults with Classic Congenital Adrenal Hyperplasia

– NBI-74788 Achieved Study Goals and Demonstrated Reductions in Key Disease Biomarkers Exceeding Predetermined Threshold for Proof-of-Concept- Based on Interim Results, Company Plans to Meet with FDA to Discuss the Registration Program in Adult and Ped… […]

No Picture
News

Trovagene to Present Data from Lead Clinical Programs of Onvansertib in AML and mCRPC at the American Association for Cancer Research Annual Meeting

SAN DIEGO, Feb. 28, 2019 /PRNewswire/ — Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, taking a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias, lympho… […]

No Picture
News

BioAtla Presents CAB-CTLA-4 And CAB-EpCAM-ADC Data At The American Association For Cancer Research Annual Meeting

Oral presentation highlights CAB-CTLA-4 pre-clinical data demonstrating expected efficacy and reduced immune side effects and toxicities as monotherapy or in combination with PD-1 inhibitorsPoster presentation of CAB-EpCAM-ADC demonstrating anti-tumor … […]

No Picture
News

Phoenix Molecular Designs to Present at BIOCOM’s 2019 Global Life Science Partnering Conference

VANCOUVER, British Columbia and SAN DIEGO, Feb. 20, 2019 /PRNewswire/ — Phoenix Molecular Designs (PhoenixMD), a privately-held biotechnology company designing precise cancer therapeutics by targeting essential kinases, announced today that Dr. San… […]

No Picture
News

Inhibrx Announces Dosing of First Patient in Phase 1 Dose-Escalation Study of INBRX-105, a Novel Multispecific PD-L1 and 4-1BB Antibody

SAN DIEGO, Feb. 19, 2019 /PRNewswire/ — Inhibrx, Inc. (Inhibrx), a clinical-stage biotechnology company developing a broad pipeline of novel biologic therapeutic candidates, announced today that dosing has begun in a Phase 1 dose-escalation clinic… […]